跳至主要内容
临床试验/NCT05638009
NCT05638009招募中不适用

The ECLA/PHRI Intervention in the Community Trial - EPIC Trial

Estudios Clínicos Latino América2 个研究点 分布在 1 个国家目标入组 2,490 人开始时间: 2022年11月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
2,490
试验地点
2
主要终点
Systolic Blood Pressure at day 120

研究概览

简要总结

EPIC is a cluster-randomized, double-blind trial to evaluate the effect of two potassium-enriched salt substitute preparations (one available in the Argentine market and one derived from it), compared to regular salt on systolic blood pressure in subjects ≥ 18 and ≤ 90 years old from Rosario department households in Santa Fe Province, Argentina.

详细描述

The effect of reduced sodium salt preparations has been evaluated in clinical studies (observational and randomized clinical trials) and in meta-analyses, and although a reduction in blood pressure was observed, they have particular characteristics that make them difficult to extrapolate their results to Western populations.

In one of these trials, conducted in rural Indian hypertensive patients, the use of a salt substitute of 75% sodium chloride and 25% potassium chloride showed a significant reduction of systolic blood pressure with a mean difference of -4.58 mmHg in 3 months from baseline to the end of the trial.

Recently, a large cluster-randomized trial conducted in 600 villages in rural areas of five provinces of China (SSaSS trial) among patients with a history of stroke or 60 years of age or elder with elevated blood pressure showed that stroke rates, major cardiovascular events and death from any cause were significantly lower with a salt substitute than with regular salt. The salt substitute used in this trial had 1/3 less sodium than regular salt and substantially more potassium. Therefore, the salt substitute led to an 8% less sodium intake but a 50% higher intake in potassium. This suggests that the greatest impact of salt substitution in this RCT may have been due to an increase in potassium intake rather than the modest decrease in sodium intake that was associated with an average reduction of 2.65 mmHg for SBP (-4.32 to -0.97) and +0.30 mmHg (-0.72 to +1.32) for DBP. In addition, the mean sodium intake in the studied population in this trial was approximately 4.2 gr/d, which is higher than the global average worldwide sodium consumption of 3.9 gr/d. In contrast, potassium intake was lower than the average global potassium intake. Therefore, several considerations that limit the applicability to other populations remain unresolved. The sodium intake of the Chinese rural population is higher than in many other countries, while the potassium intake is relatively low. In addition, in many countries commercially available foods may have added sodium chloride for preservation and thus increase the amount of sodium to the diet. Therefore, the use of salt substitutes would not fully account for salt intake in most cases. Finally, Chinese social and environmental features may be somewhat different to most western countries.

EPIC's investigators stated the hypothesis that salt substitutes could lower systolic blood pressure in a dose-response mode. Therefore, they propose to conduct a randomized cluster trial to evaluate the effect of consuming two doses enriched potassium salt substitutes preparations compared to regular salt intake on systolic blood pressure in individuals from Rosario department.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects ≥ 18 and ≤ 90 years old will be included, with no specific clinical conditions from households that meets the following criteria:
  • The household must be composed of at least 2 individuals
  • At least 1 of the individuals included must be over 40 years of age
  • The household must be located in Rosario department, Santa Fe province, Argentina

排除标准

  • Households will be excluded if a any household member has a at least one of the following contraindication to the salt substitute used in the trial:
  • use of a potassium-sparing diuretic
  • use of a potassium supplement
  • known history of hyperkalemia
  • use of salt reduced in sodium and enriched in potassium by medical indication
  • do not consume any type of salt for medical indication
  • known primary or secondary hyperaldosteronism
  • known severe kidney disease (routine biochemical measurement of kidney function will not be performed in household members not included in the study).
  • Pregnancy or lactation
  • Evidence of hyperkalemia and/or a creatinine clearance (calculated through the CKD-EPI formula <30 ml/min/1.73m2) in baseline blood laboratory. For those participants who consent to be tested, blood sample will be used. For those participant who has a laboratory test performed with those biomarkers in the past 6 months those results will be considered
  • Households in which any of the study participants consume more than 50% of their meals prepared outside their home will also be excluded.

结局指标

主要结局

Systolic Blood Pressure at day 120

时间窗: 120 days

Systolic Blood Pressure will be measured by a standardized automated device

次要结局

  • Hyperkalemia(120 days)
  • Salt substitutes acceptance and incorporation into the diet(120 days)
  • Diastolic Blood Pressure at day 120(120 days)
  • Mean arterial pressure (MAP) at day 120(120 days)

研究者

发起方
Estudios Clínicos Latino América
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验